Related Experiment Video
Updated: May 3, 2026

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
Published on: April 17, 2021
The effect of pindolol on the two years mortality after complicated myocardial infarction
Abstract:
The effect of oral pindolol 15 mg daily was compared with placebo in 529 patients who had electrical and/or mechanical complications after an acute myocardial infarction. The study was multicentric (five in Sweden, two in Australia) and patients were allocated in a stratified manner to placebo (266 patients) or pindolol (263 patients). Treatment was started 1--21 days after infarction and patients were followed for 2 years. Forty-seven patients (17.7%) in the placebo group and 45 patients (17.1%) in the pindolol group died. In patients who commenced therapy later than 5 days after myocardial infarction mortality was 18% lower in the pindolol group and there was an even greater difference in patients who commenced therapy after 12 days. Patients who were on digitalis therapy had a lower mortality if treated with pindolol. The apparent improvement in prognosis in patients treated in Sweden compared to Australia may have been due to later entry of patients. This study suggests that improvement in prognosis when beta blocking drugs are given after myocardial infarction may only apply to certain groups of patients. No benefit is gained by commencing an oral beta blocking drug immediately and such therapy need not be started before 1 week or more after the myocardial infarct.
More Related Videos
04:29A Modified Simple Method for Induction of Myocardial Infarction in Mice
Published on: December 3, 2021
05:41Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control
Published on: December 16, 2022
Related Concept Videos
Time Course of Drug Effect
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
Heart Failure Drugs: β-Blockers
Antianginal Drugs: Nitrates and β-Blockers
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Myocarditis III: Medical Management